The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Van Oostrum, J.
* Articles by Voshol, H.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Van Oostrum, J.
* Articles by Voshol, H.
Related Collections
* Genetics
Am J Psychiatry 159:208, February 2002
© 2002 American Psychiatric Association


Images in Neuroscience

The Human Genome: Proteomics

Jan Van Oostrum, Ph.D., and Hans Voshol, Ph.D.
Basel, Switzerland

Proteins are the final expression products of genes, the functional translation of the genomic information, conveyed by mRNA. Some experimentalists ask, Why measure mRNA at all, if it is only an intermediate on the way to production of the functional protein products? The most important reasons are of a practical nature: nucleic acid analyses are relatively easy, are very sensitive by virtue of the possibility of amplification, and can be readily automated. However, all of this does not diminish the need for protein information, as well as RNA expression, to fully characterize the information content of cells, tissues, or body fluids. Moreover, only the characterization of the proteins themselves can reveal posttranslational modifications (e.g., phosphorylation, sulfation, glycosylation) and give insight into protein-protein interactions and subcellular localization, thus providing clues about function. The large-scale identification of proteins contained in a tissue is often referred to as "proteomics." It is frequently carried out by using two-dimensional gel electrophoresis as a separation method and followed up with mass spectroscopy for the identification and characterization of proteins of interest. Descriptively, the target tissue is harvested and the proteins solubilized. The crude protein mixture is then applied to a gel and separated according to electric charge along the first dimension followed by a separation according to size along a second dimension, perpendicular to the first one. The resulting proteome image (illustrated in the figure) is a complex array of spots, each of which represents an individual protein species. Analysis of the proteome image requires specialized computer programs that can match spot patterns across the different images, thus allowing for a comparison and statistical evaluation of protein profiles between tissues and across samples. Mass spectroscopy of an excised spot is the technique used to identify and characterize the protein. The mass spectroscopic identification of gel-separated proteins has been a highly important breakthrough in proteomics in the 1990s because it extends protein analysis far beyond the mere display of tissue protein patterns. The experimental comparison of the protein content from two different tissues (e.g., diseased versus healthy tissue) can directly answer the question of what protein differences characterize a specific tissue in a brain disease. This is illustrated in the figure, which depicts a proteome image of a specific brain area of a patient with schizophrenia (left) compared with that of a healthy individual (right). Besides a large number of common features, such as the two actin isoforms in the red rectangle, there are also a number of obvious differences, e.g., the presence or absence of isoforms of the glial acidic fibrillary protein (blue rectangle). This illustrates the intricacy of working with human tissue, where most of these differences are attributable to natural variation between individuals. In the analysis of complex brain diseases such as schizophrenia, the challenge for proteomics is to provide methods and tools to filter out the disease-specific changes from polymorphisms that simply discriminate one individual from another.



View larger version (101K):
[in this window]
[in a new window]
 

Figure

Two-dimensional gels of brain tissue extracts from a subject with schizophrenia and a healthy comparison subject, displaying proteins with iso-electric points (pI) between 4.6 and 5.4 and molecular weights between 200 and 10 kilodaltons (kD).



Footnotes

Address reprint requests to Dr. Tamminga, Maryland Psychiatric Research Center, University of Maryland, P.O. Box 21247, Baltimore, MD 21228; ctamming{at}mprc.umaryland.edu (e-mail). The image is courtesy of Drs. Van Oostrum and Voshol, Novartis Pharma.





This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by Van Oostrum, J.
* Articles by Voshol, H.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Van Oostrum, J.
* Articles by Voshol, H.
Related Collections
* Genetics


Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org